Roche Holding AG (RHHVF)
| Market Cap | 326.62B +30.8% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 20.11 |
| Forward PE | 15.40 |
| Dividend | 20.68 (5.07%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 2 |
| Average Volume | 11,270 |
| Open | 371.83 |
| Previous Close | 371.06 |
| Day's Range | 371.83 - 403.29 |
| 52-Week Range | 300.00 - 490.33 |
| Beta | 0.33 |
| RSI | 51.57 |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Roche (RHHBF) to Acquire PathAI for $1.1B to Enhance Digital Pathology Services
Roche (RHHBF) to Acquire PathAI for $1.1B to Enhance Digital Pathology Services
Roche Acquires PathAI for $750 Million, Stock Impact Expected
Roche Acquires PathAI for $750 Million, Stock Impact Expected
Roche announces agreement to acquire PathAI
Roche (RHHBY) announced that it has entered into a definitive merger agreement to acquire PathAI, a U.S.-based company in digital pathology and AI-powered technology for pathology laboratories and the...
Roche Enters $750 Mln Merger Deal To Acquire PathAI To Expand AI-Driven Diagnostics
(RTTNews) - Roche (RHHBY), a healthcare company, announced on Thursday that it has entered into a definitive merger agreement to acquire PathAI, a digital, AI-powered technology firm serving pathology...
Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools
The deal seeks to bolster the artificial-intelligence offerings of Roche's diagnostics division, helping to accelerate clinical-therapy development.
Switzerland's Roche agrees to acquire US-based PathAI
Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further miles...
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
Basel, 7 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered...
The Zacks Analyst Blog Highlights Microsoft, Bank of America, Roche and GSI Technology
Microsoft faces pressure from capacity constraints and competition, even as AI momentum and Azure growth drive demand beyond available supply.
Top Analyst Reports for Microsoft, Bank of America & Roche
Microsoft faces Azure capacity limits and rising competition, but AI momentum and Copilot adoption fuel cloud growth and enterprise demand.
Roche To Showcase Broad Ophthalmology Data Portfolio At ARVO 2026, Today
(RTTNews) - Roche (RHHBY) will present one of the largest ophthalmology data packages at this year's ARVO Annual Meeting, highlighting new real-world findings and clinical updates across its marketed ...
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will showcase key real-world, product and pipeline data from ...
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
Basel, 30 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association for Resear...
Zealand Pharma, Roche to advance petrelintide for weight management to Phase 3
Zealand Pharma A/S (ZLDPF) announced formal endorsement to advance petrelintide, an amylin analog for chronic weight management, into Phase 3 trials with its partner Roche (RHHBY). The initiation is p...
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME' Campaign
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced the launch of All Eyes on DME, a campaign developed in partnership with adv...
Roche upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Sarita Kapila upgraded Roche (RHHBY) to Equal Weight from Underweight with an unchanged price target of CHF 295. The firm says the company’s recent pipeline setbacks now
Roche Holding AG Earnings Call Transcript: Q1 2026
Sales grew 6% at constant exchange rates in Q1 2026, led by strong Pharma and Diagnostics performance, despite currency headwinds and China pricing reforms. Multiple regulatory filings and positive clinical data support a robust pipeline, with guidance for mid-single-digit sales and high single-digit EPS growth reaffirmed.
Roche CEO: Obesity drug pipeline could challenge market leaders
Thomas Schinecker, CEO at Roche discusses Q1 earnings, and explains the timeline behind the company's launch of their GLP-1 drug offering.
Europe risks falling further behind in medicine race, warns Roche CEO
Europe risks falling further behind the United States and China in pharmaceutical research and innovation because of "mind-blowing" bureaucracy and government policies threatening jobs, Roche Chief E...
Roche (RHHBY) Reports Q1 Sales Decline Amid Currency Challenges
Roche (RHHBY) Reports Q1 Sales Decline Amid Currency Challenges
Roche Reports Sales Decline Amid Strong Swiss Franc and Generic Competition
Roche Reports Sales Decline Amid Strong Swiss Franc and Generic Competition
Roche reports Q1 group sales CHF 14.7B vs. CHF 15.4B last year
In the first three months of 2026, Roche (RHHBY) sales were +6% at CER, -5% when reported in CHF, to CHF 14.7B due to strong demand for pharmaceutical products and
Roche expects increase in group sales in mid single digit range for FY26
Roche (RHHBY) expects an increase in Group sales in the mid single digit range CER for 2026. Core earnings per share are targeted to develop in the high single digit
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
Roche sales fell 5% in the first quarter, but increased 6% in constant exchange rates. The appreciation of the Swiss franc against most currencies, notably the U.S. dollar, had a significant impact on...
Roche Backs Full-Year View as Quarterly Sales Rise
Roche confirmed its full-year guidance after reporting a first-quarter rise in sales driven by high demand for its innovative medicines and diagnostics.
Roche Q1 sales down on forex effects
Swiss drugmaker Roche said on Thursday that its first-quarter sales declined because of negative foreign exchange effects but rose at constant exchange rates.